Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Lymphoid 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 451Melanoma 287Squamous Cell Carcinoma of Head and Neck 229Parkinson Disease 4, Autosomal Dominant Lewy Body 188Neoplasms 180Triple Negative Breast Neoplasms 162Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 141Colorectal Neoplasms 140Carcinoma, Renal Cell 129Head and Neck Neoplasms 120Stomach Neoplasms 103Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 80Pancreatic Neoplasms 80Endometrial Neoplasms 74Carcinoma, Hepatocellular 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 48Sarcoma 43Carcinoma 42Small Cell Lung Carcinoma 39Glioblastoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Lymphoma 34

Interventions

Cyclophosphamide 13fludarabine 7Trabectedin 4Radiation Dose Hypofractionation 3seclidemstat 2pembrolizumab 2Topotecan 2Interferon-gamma 2selinexor 1ribociclib 1pazopanib 1palbociclib 1mirdametinib 1itacitinib 1interferon gamma-1b 1fludarabine phosphate 1cytochrome C synthetase 1brostallicin 1baricitinib 1atezolizumab 1aldesleukin 1X-Rays 1Specimen Handling 1Sirolimus 1Radiotherapy 1Radiation 1Proton Therapy 1Pioglitazone 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Liposarcoma, Myxoid × pembrolizumab × Clear all
NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Valo Therapeutics Oy

Phase 1 Recruiting
15 enrolled
BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT03063632 2023-10-25

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 15 charts
LymphoidSarcoma

Mycosis Fungoides, Sezary Syndrome, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡